Cancer Research: An Interdisciplinary Approach [[electronic resource] /] / edited by Nima Rezaei |
Autore | Rezaei Nima |
Edizione | [1st ed. 2023.] |
Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 |
Descrizione fisica | 1 online resource (614 pages) |
Disciplina | 616.9940072 |
Collana | Interdisciplinary Cancer Research |
Soggetto topico |
Cancer
Cancer—Treatment Stem cells Cytology Medical genetics Immunology Cancer Biology Cancer Therapy Cancer Stem Cells Cell Biology Medical Genetics |
ISBN | 3-031-32458-7 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Interdisciplinary Approaches in Cancer Research -- Role of Immune Cells in the Tumor Microenvironment -- Spatial Transcriptomic Approaches for Understanding the Tumor Microenvironment (TME) -- Role of Mesenchymal Stem/Stromal Cells in Cancer Development -- Cancer-associated Fibroblasts and Their Role in Cancer Progression -- The Role of Tumoroids in Cancer Research -- Myokines Expression in Cancer Cachexia -- Epigenetics in Cancer Biology -- Epigenetic Regulation of Cancer by Natural Touch: Phytochemicals and Epigenetic Regulation -- Telomerase Reverse Transcriptase in Humans: From Biology to Cancer Immunity -- Molecular Mechanisms of Metal-induced Carcinogenesis -- Epi-drugs Targeting RNA Dynamics in Cancer -- Oncologic Emergencies: Pathophysiology, Diagnosis, and Initial Management -- Malignancies in Inborn Errors of Immunity -- Hematopoietic Stem Cell Transplantation in Patients with Inborn Errors of Immunity and Malignancy -- Personalized Immuno-oncology with Immunodeficiency Mouse Models -- Allergy and Cancer: New Perspectives -- Depression and Cancer: the Inflammatory Bridge -- Impact of Cancer-Related Sarcopenia on Systemic Immune Status -- Surveillance of Subclinical Cardiovascular Complications in Childhood Cancer Survivors: Exercise as a Diagnostic and Therapeutic Modality. |
Record Nr. | UNINA-9910734848103321 |
Rezaei Nima
![]() |
||
Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Gastrointestinal Cancers: An Interdisciplinary Approach [[electronic resource] /] / edited by Nima Rezaei |
Autore | Rezaei Nima |
Edizione | [1st ed. 2023.] |
Pubbl/distr/stampa | Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 |
Descrizione fisica | 1 online resource (405 pages) |
Disciplina |
571.978
616.994 |
Collana | Interdisciplinary Cancer Research |
Soggetto topico |
Cancer
Cancer - Treatment Oncology Immunotherapy Tumors - Immunological aspects Nanomedicine Gastrointestinal Neoplasms Tumor Microenvironment Cancer Biology Cancer Therapy Tumour Immunology Cancer Nanotechnology |
ISBN | 3-031-48371-5 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Interdisciplinary Approach in Gastrointestinal Cancers -- Gastrointestinal Cancers: What Is the Real Board of Microenvironment and the Role of Microbiota-Immunity Axis -- Epithelial-Mesenchymal Transition in Gastrointestinal Cancer: From a Basic to a Clinical Approach -- Metabolomics of Gastrointestinal Cancers -- Deregulation of Immune System in Gastric Cancer Development, How Immune Nutrition Might Restore the Functions of Immune Cells -- Helicobacter pylori Virulence Factors, Pathogenicity, and Gastric Cancer -- Gastric Cancer and Helicobacter pylori -- Role of Neuromodulators in Regulation of the Tumor Microenvironment of Gastric and Colorectal Cancers -- The Role of Tumor Microenvironment in Colon Cancer -- Unraveling the Esophageal Cancer Tumor Microenvironment: Insights and Novel Immunotherapeutic Strategies -- The Interplay Between Immunity and Gut Microbiota in Colon Cancer -- Immunotherapy in Gastrointestinal Cancer Focusing on CAR-T Cell Therapy -- Development of Biocompatible Nanocarriers for the Treatment of Colorectal Cancer -- Challenges of Onco-therapeutics in Early Onset Colorectal Cancer -- Unintentional Weight Loss and Malnutrition After Esophageal Cancer and Treatment -- Current Clinical Landscape of Immunotherapeutic Approaches in Pancreatic Cancer Treatment. The Tumor Microenvironment in Pancreatic Cancer and Challenges to Immunotherapy. . |
Record Nr. | UNINA-9910799498103321 |
Rezaei Nima
![]() |
||
Cham : , : Springer Nature Switzerland : , : Imprint : Springer, , 2023 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Human Brain and Spinal Cord Tumors: From Bench to Bedside. Volume 2 [[electronic resource] ] : The Path to Bedside Management / / edited by Nima Rezaei, Sara Hanaei |
Autore | Rezaei Nima |
Edizione | [1st ed. 2023.] |
Pubbl/distr/stampa | Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023 |
Descrizione fisica | 1 online resource (754 pages) |
Disciplina | 616.9948061 |
Altri autori (Persone) | HanaeiSara |
Collana | Advances in Experimental Medicine and Biology |
Soggetto topico |
Medicine—Research
Biology—Research Neurology Internal medicine Immunology Spinal Cord Neoplasms Brain Neoplasms Biomedical Research Internal Medicine |
ISBN | 3-031-23705-6 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto | Chapter 1. Malignant Glioma -- Chapter 2. Benign Glioma -- Chapter3. Meningioma and Other Meningeal Tumors -- Chapter4. Epondymomas in Pediatric and Adults -- Chapter5. Medulloblastomas in Pediatric and Adults -- Chapter6. Benign and Malignant Tumors of The Pineal Region -- Chapter7. The Tumors of Choroid Plexus and Other Ventricular Tumors -- Chapter8. Embryonal Tumors of The Central Nervous System with Multilayered Rosettes and Atypical Teratoid/Rhabdoid Tumors -- Chapter9. Glioneuronal and Neuronal Tumors of the Central Nervous System -- Chapter10. Benign and Malignant Tumors of the Pituitary Gland -- Chapter11. Craniopharyngioma in Pediatric and Adults -- Chapter12. Schwannomas of Brain and Spinal Cord -- Chapter13. Other Nerve-Sheet Tumors of Brain and Spinal Cord -- Chapter14. Hemangioblastomas and Other Vascular Originating Tumors of Brain or Spinal Cord -- Chapter15. Brain and Spinal Cord Tumors of Embryonic Origin -- Chapter16. Brain and Spinal Tumors Originating from the Germ Line Cells -- Chapter17. Benign Brain and Spinal Tumors Originating from Bone or Cartilage -- Chapter18. Benign Spinal Tumors -- Chapter19. Other Less Prevalent Tumors of the Central Nervous System -- Chapter20. Brain and/or Spinal Cord Tumors Accompanied with Other Diseases or Syndromes -- Chapter21. Psychological and Psychiatric Aspects of Brain and Spinal Cord Tumors -- Chapter22. A Brief Explanation on Surgical Approaches for Treatment of Different Brain Tumors. |
Record Nr. | UNINA-9910734875803321 |
Rezaei Nima
![]() |
||
Cham : , : Springer International Publishing : , : Imprint : Springer, , 2023 | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|
Vaccines for cancer immunotherapy : an evidence-based review on current status and future perspectives / / Nima Rezaei, Mahsa Keshavarz-Fathi |
Autore | Rezaei Nima |
Pubbl/distr/stampa | London, United Kingdom : , : Academic Press, an imprint of Elsevier, , [2019] |
Descrizione fisica | 1 online resource (185 pages) |
Disciplina | 616.994061 |
Soggetto topico | Cancer - Immunotherapy |
ISBN | 0-12-814040-2 |
Formato | Materiale a stampa ![]() |
Livello bibliografico | Monografia |
Lingua di pubblicazione | eng |
Nota di contenuto |
Front Cover -- Vaccines for Cancer Immunotherapy -- Vaccines for Cancer Immunotherapy: An Evidence-Based Review on Current Status and Future Perspectives -- Copyright -- Contents -- List of Contributors -- Preface -- 1 - CANCER IMMUNOLOGY -- INNATE AND ADOPTIVE IMMUNITY -- ACTIVATING IMMUNE CELLS -- MATURE DCS -- CLASSICALLY ACTIVATED MACROPHAGES (M1) -- GRANULOCYTES -- B LYMPHOCYTES -- T HELPER LYMPHOCYTES -- CYTOTOXIC T LYMPHOCYTES -- γδ T LYMPHOCYTES -- NATURAL KILLER T CELLS -- NATURAL KILLER CELLS -- INHIBITORY IMMUNE CELLS -- TOLEROGENIC DCS -- ALTERNATIVELY ACTIVATED MACROPHAGES (M2S) -- MYELOID-DERIVED SUPPRESSOR CELLS -- REGULATORY T CELLS -- REGULATORY B CELLS -- IMMUNOEDITING HYPOTHESIS -- ELIMINATION -- Cells -- Interferons -- Perforin -- Tumor Cell Recognition -- EQUILIBRIUM -- ESCAPE -- Defects in Tumor Antigen Processing, Presentation, and Recognition -- Lack of Activating Mechanisms -- Inhibitory Mechanisms and Immunosuppressive State -- Resistant Tumor Cells -- REFERENCES -- 2 - IMMUNOTHERAPEUTIC APPROACHES IN CANCER -- HISTORY -- APPROACHES OF CANCER IMMUNOTHERAPY -- PASSIVE VERSUS ACTIVE IMMUNOTHERAPY -- PASSIVE IMMUNOTHERAPY FOR CANCER -- Cytokines -- Monoclonal Antibodies (mAbs) -- Adoptive Cell Therapy -- ACTIVE IMMUNOTHERAPY FOR CANCER -- Vaccines -- Peptide Vaccine -- Tumor Cell Vaccine -- Dendritic Cell Vaccine -- Genetic Vaccine -- Checkpoint Inhibitors -- Oncolytic Viruses -- MECHANISM-BASED IMMUNOTHERAPIES: INTERACTIONS BETWEEN TUMOR CELLS AND THE IMMUNE SYSTEM -- TUMOR ANTIGEN EXPRESSION, RELEASE AND PRESENTATION -- T CELL PRIMING AND ACTIVATION -- TRAFFICKING AND INFILTRATION OF T CELLS TO TUMOR -- TUMOR CELL RECOGNITION AND EFFECTOR FUNCTION OF T CELLS -- REFERENCES -- 3 - VACCINES, ADJUVANTS, AND DELIVERY SYSTEMS -- DEFINITION AND CLASSIFICATION -- CANCER VACCINE -- PREVENTIVE CANCER VACCINE.
THERAPEUTIC CANCER VACCINE -- ADJUVANTS -- NONSPECIFIC ADJUVANTS -- CYTOKINES AND CHEMOKINES -- STIMULATORS OF THE INNATE IMMUNE SYSTEM -- C-type Lectin Receptor Ligands -- RIG-like Receptor Ligands -- Stimulator of Interferon Gene Ligands -- Toll like Receptor Ligands -- TLR2 Agonists -- TLR3 Agonists -- TLR4 Agonists -- TLR7 and TLR8 Agonists -- TLR9 Agonists -- Other Immunomodulatory Adjuvants -- Adjuvant Systems -- VECTORS AND DELIVERY SYSTEM -- ROUTE OF ADMINISTRATION -- REFERENCES -- 4 - TUMOR ANTIGENS -- INTRODUCTION -- IDENTIFICATION OF TUMOR ANTIGENS -- OVEREXPRESSED PROTEINS AND MUTATED ANTIGENS IN TUMOR CELLS -- EPITOPE SPREADING -- TUMOR-ASSOCIATED ANTIGENS -- TUMOR-SPECIFIC ANTIGENS -- NEOANTIGENS -- GLYCOLIPIDS AND GLYCOPROTEINS AS ANTIGENS -- MONO-EPITOPE VERSUS POLY-EPITOPE ANTIGEN -- REFERENCES -- 5 - STRATEGY OF ALLOGENEIC AND AUTOLOGOUS CANCER VACCINES -- AUTOLOGOUS CANCER VACCINES -- IN VIVO STUDIES AND CLINICAL IMPLICATIONS -- ALLOGENEIC CANCER VACCINES -- IN VITRO/IN VIVO STUDIES AND CLINICAL IMPLICATIONS -- REFERENCES -- 6 - PERSONALIZED CANCER VACCINE -- INTRODUCTION ON PERSONALIZED MEDICINE -- PERSONALIZED MEDICINE IN CANCER PATIENTS -- SCREENING OF CANCER -- CLASSIFICATION OF TUMORS -- TARGETED THERAPY AND USING PREDICTIVE BIOMARKERS -- SAFETY OF MEDICATION -- PROGNOSTIC BIOMARKERS -- NEOANTIGENS AND PERSONALIZED CANCER VACCINES -- PERSONALIZED CANCER VACCINES IN CLINICAL STUDIES -- WHOLE TUMOR CELL VACCINES -- PEPTIDE/PROTEIN-BASED VACCINE -- IMMUNE CELL-BASED VACCINES -- GENETIC-BASED VACCINE -- REFERENCES -- 7 - WHOLE TUMOR CELL VACCINE FOR CANCER -- TUMOR CELL LYSATES -- TUMOR-DERIVED EXOSOMES -- IRRADIATED GENE-MODIFIED TUMOR CELL VACCINE -- CLINICAL TRIALS -- APPROVED VACCINE -- ADVANTAGES AND DISADVANTAGES -- OPTIMIZATION -- REFERENCES -- 8 - PEPTIDE AND PROTEIN VACCINES FOR CANCER -- PEPTIDE-BASED VACCINE. PROTEIN-BASED VACCINE -- MECHANISM OF ACTION -- CLINICAL TRIALS -- PEPTIDE-BASED VACCINE -- Gp100 -- BLP25 -- PROTEIN BASED VACCINE -- MAGE-A3 -- EGF-P64k -- ADVANTAGES AND DISADVANTAGES -- OPTIMIZATION -- REFERENCES -- 9 - IMMUNE CELL VACCINE FOR CANCER -- IMMUNE CELL VACCINE -- MECHANISM OF ACTION -- CLINICAL TRIALS -- IMMATURE DENDRITIC CELLS PULSED WITH TUMOR CELL LYSATES -- MATURE DENDRITIC CELLS PULSED WITH TUMOR CELL LYSATES -- DENDRITIC CELLS LOADED WITH TUMOR-DERIVED RNA -- DENDRITIC CELLS PULSED WITH PEPTIDES -- DENDRITIC CELLS LOADED WITH TUMOR CELLS -- APPROVED VACCINE -- ADVANTAGES AND DISADVANTAGES -- OPTIMIZATION -- REFERENCES -- 10 - GENETIC VACCINE FOR CANCER -- MECHANISM OF ACTION -- MECHANISM OF ACTION OF DNA VACCINES -- MECHANISM OF ACTION OF RNA VACCINES -- DNA VACCINE -- CLINICAL TRIALS -- DELIVERY, IMMUNOGENICITY AND IMMUNE RESPONSE -- ADVERSE EFFECTS -- RNA VACCINE -- CLINICAL TRIALS -- DELIVERY, IMMUNOGENICITY AND IMMUNE RESPONSE -- ADVERSE EFFECTS -- ADVANTAGES AND DISADVANTAGES -- ADVANTAGES AND DISADVANTAGES OF DNA VACCINES -- ADVANTAGES OF RNA VACCINES -- OPTIMIZATION -- DNA VACCINE OPTIMIZATION -- RNA VACCINE OPTIMIZATION -- REFERENCES -- 11 - CANDIDATE CANCERS FOR VACCINATION -- VACCINES FOR PROSTATE CANCER -- VACCINES FOR MELANOMA -- VACCINES FOR LUNG CANCER -- VACCINES FOR COLORECTAL CANCER -- VACCINES FOR BREAST CANCER -- REFERENCES -- 12 - OBSTACLES IN THE DEVELOPMENT OF THERAPEUTIC CANCER VACCINES -- TUMOR ANTIGENS -- TUMOR BURDEN -- CLINICAL RESPONSE VERSUS IMMUNE RESPONSE -- PRIOR TREATMENTS -- DESIGNING CLINICAL TRIALS -- REFERENCES -- 13 - COMBINATION THERAPY: CANCER VACCINES AND OTHER THERAPEUTICS -- CHEMOTHERAPY COMBINED WITH VACCINES -- RADIATION COMBINED WITH VACCINES -- TARGETED THERAPIES COMBINED WITH IMMUNOTHERAPY -- HORMONE THERAPY COMBINED WITH VACCINE. VACCINE COMBINED WITH OTHER IMMUNOTHERAPEUTIC MODALITIES -- REFERENCES -- 14 - CONCLUDING REMARKS AND FUTURE PERSPECTIVES ON THERAPEUTIC CANCER VACCINES -- CONCLUDING REMARKS -- BASIC IMMUNOLOGY OF CANCER VACCINES -- APPROVED VACCINES -- NEOANTIGEN VACCINES -- PREVENTIVE CANCER VACCINE -- CONSIDERATIONS TO FULFILL AMBITIONS -- REFERENCES -- Index -- Back Cover. |
Record Nr. | UNINA-9910583347503321 |
Rezaei Nima
![]() |
||
London, United Kingdom : , : Academic Press, an imprint of Elsevier, , [2019] | ||
![]() | ||
Lo trovi qui: Univ. Federico II | ||
|